HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of PGI2 and thromboxane antagonist on liver ischemic injury.

Abstract
Thromboxane, prostacyclin and their ratio could play an important role in the ischemic liver injury. To study this hypothesis, thromboxane and prostacyclin were measured by RIA after incubation of liver tissues removed during and after an ischemia of 90 min in male Wistar rats. The thromboxane to prostacyclin ratio increases during this period. In order to examine if this change could influence the survival rate of animals submitted to the same period of ischemia, drugs able to reduce the relative predominance of thromboxane were infused. The survival rate was not modified by administration of Iloprost or Daltroban, the antagonist of the thromboxane receptors. By contrast, imidazole, an inhibitor of thromboxane synthetase, significantly increased the survival rate. The same result was obtained with the administration of Daltroban plus Iloprost, suggesting that the reduction of thromboxane action associated with the increase of PGI2 level reduces the ischemic injury.
AuthorsT Besse, T Gustin, N Claeys, P Schroeyers, L Lambotte
JournalEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes (Eur Surg Res) Vol. 21 Issue 3-4 Pg. 213-7 ( 1989) ISSN: 0014-312X [Print] Switzerland
PMID2478369 (Publication Type: Journal Article)
Chemical References
  • Imidazoles
  • Phenylacetates
  • Sulfonamides
  • Thromboxane B2
  • 6-Ketoprostaglandin F1 alpha
  • imidazole
  • Epoprostenol
  • Iloprost
  • daltroban
Topics
  • 6-Ketoprostaglandin F1 alpha (analysis)
  • Animals
  • Epoprostenol (pharmacology)
  • Iloprost
  • Imidazoles (pharmacology)
  • Ischemia (metabolism)
  • Liver (analysis, blood supply, drug effects)
  • Male
  • Phenylacetates (pharmacology)
  • Rats
  • Rats, Inbred Strains
  • Sulfonamides (pharmacology)
  • Thromboxane B2 (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: